ImmVira Opens In-House Production Facility for Oncolytic Viruses
publication date: Jul 23, 2021
ImmVira, a Shenzhen oncolytic virus company, opened its pilot-scale production line for next-gen oncolytic viruses with capacity for Phase I/II clinical trials. The company said its strategy combines in-house manufacturing with CDMO, allowing ImmVira to innovate on CMC techniques and improvements in production efficiency. ImmVira's lead product, MVR-T3011, is a genetically modified oncolytic herpes simplex virus that includes two exogenous genes -- PD-1 antibody and IL-12 -- to enhance the immune response. One month ago, ImmVira dosed the first patients in a China/US Phase II trial of MVR-T3011. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.